Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

por Beck, Lisa A., Thaçi, Diamant, Deleuran, Mette, Blauvelt, Andrew, Bissonnette, Robert, de Bruin-Weller, Marjolein, Hide, Michihiro, Sher, Lawrence, Hussain, Iftikhar, Chen, Zhen, Khokhar, Faisal A., Beazley, Bethany, Ruddy, Marcella, Patel, Naimish, Graham, Neil M. H., Ardeleanu, Marius, Shumel, Brad
Publicado 2020